Dipeptidylpeptidase 4 (DPP-4) inhibitors are a new class of blood glucose-lowering drug, have been approved for treatment of type 2 diabetes, and take the advantage of having low risk of hypoglycemia and neutral effect on body weight [6-9]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.